Overview
TMS Health Solutions operates a network of outpatient TMS therapy clinics across the United States, providing transcranial magnetic stimulation treatment for major depressive disorder and OCD.
TMS Health Solutions operates a network of outpatient clinics specializing in transcranial magnetic stimulation (TMS) therapy, a non-invasive neuromodulation treatment for major depressive disorder and obsessive-compulsive disorder. The company delivers evidence-based TMS protocols that use magnetic pulses to stimulate specific brain regions implicated in mood and anxiety disorders. Their clinic-based model enables patients to receive treatment in accessible community settings while maintaining clinical oversight and outcomes tracking. By combining FDA-approved technology with a distributed provider network, TMS Health Solutions makes advanced neuromodulation therapy available to patients across the United States.
Based in Sacramento, California, TMS Health Solutions has established itself as a significant player in the outpatient neuromodulation market through its multi-clinic expansion strategy. The company has grown its footprint to serve thousands of patients seeking alternatives to medication-only approaches for treatment-resistant depression and OCD. Their privately-funded model has allowed them to maintain focus on clinical outcomes and patient access while competing in an increasingly crowded neurotech landscape.
TMS Health Solutions matters to the neurotech industry because it demonstrates the viability of clinic-based neuromodulation delivery at scale, validating a business model that bridges cutting-edge neurotechnology with practical healthcare access. As mental health conditions continue to affect millions globally, their approach of combining FDA-approved devices with trained clinical staff addresses both the efficacy and implementation challenges that limit neurotech adoption. The company's success reinforces investor and clinical interest in non-invasive neuromodulation as a legitimate therapeutic category alongside traditional psychiatry.
More in Neuromodulation
Latest industry news
Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
2026-06-15 · Funding
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
⚡ Neuromodulation
Location
Sacramento, CA, USA
Funding
Private
Website
www.tmshealth.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →